Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If FDA delays to approve the product, BIEL can add 5 more billion shares to maintain the company.
BIEL can be 25 cents easily by end of 2019 year.
The annual cost of chronic pain just in US is $635 billion.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
Paul Knopick asked me to circulate the video. Please circulate the video to your friends.
--------- Forwarded message ---------
From: E & E Communications <pknopick@eandecommunications.com>
Date: Wed, Nov 7, 2018 at 12:30 PM
Subject: BioElectronics Video
To: <nchintha@gmail.com>
Release #:812-176152-rl-1176180:
Please circulate the video below to the email list:
Please circulate the video below to the email list:
I got email from Paul today to circulate the video. Please circulate the video to your friends.
--------- Forwarded message ---------
From: E & E Communications <pknopick@eandecommunications.com>
Date: Wed, Nov 7, 2018 at 12:30 PM
Subject: BioElectronics Video
To: <nchintha@gmail.com>
Release #:812-176152-rl-1176180:
Please circulate the video below to the email list:
GetSeriousOK, Do you have any idea how to bring back return customers to buy ActiPatches more? If you have any idea, please share it to company as a shareholder.
Today is Nov 6th. So we no need worry about the settlement or Do we still wait until Nov 16th?
BIEL can be 25 cents easily.
The annual cost of chronic pain just in US is $635 billion.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
Revenues are not important now. Once BIEL receives a Full clearance, then it will be easy to market to generate more revenues.
Even If buyout happens, the buyout offer would be more than $5 billion.
BIEL needs only $5 billion from $635 billion per year to reach 25 cents.
The annual cost of chronic pain just in US is $635 billion.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
BIEL needs only $5 billion from $635 billion per year to reach 25 cents.
The annual cost of chronic pain just in US is $635 billion.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
BIEL can be easily reached 25 cents.
The annual cost of chronic pain just in US is $635 billion.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
The annual cost of chronic pain just in US is $635 billion.
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
$635 billion a year
Health economists have reported the annual cost of chronic pain in the United States is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.
If BIEL captures only $5 billion per year from $635 billion, it will easily reach to 25 cents per share.
I agree with toohot. DewmBoom, srinsocal, seven-up, Simpsonly and Dr. Deep are an inspiration for every long.
FDA has a lot of departments. So ActiPatch falls under the medical device department. Looks like Medical device department is little slower than other departments.
Good times started for BIEL. It can be a $5 to $10 billion company by end of 2019 year.
Set The Standard_Johnson & Johnson $JNJ Looks To Expand Opiate Elimination Portfolio With BioElectronics $BIEL ActiPatch Therapy, Discussions To Begin Monday In Maryland
I can also see it on https://twitter.com/stocktweetshq
0 replies 3 retweets 0 likes
Reply Retweet 3 Like Direct message
Rumors, Murmurs & Buzz Retweeted
Rumors, Murmurs & Buzz
?
@StockTweetsHQ
23h23 hours ago
More
Set The Standard_Johnson & Johnson $JNJ Looks To Expand Opiate Elimination Portfolio With BioElectronics $BIEL ActiPatch Therapy, Discussions To Begin Monday In Maryland
https://rumormurmursbuzz.blogspot.com/2018/11/set-standardjohnson-johnson-jnj-looks.html …
$MOGO $CHSCO $EXD $SGOC $HPI $ALPpQ $JPMpE $BMRC $CVV $REED $AGD $JTD $SONA $KMM
BIEL CAN BE $5 BILLION COMPANY by end of 2019 year.
Biel is going to focus on marketing once they receive a full FDA approval. It easily goes up 23 or 25 cents by end of 2019 year.
Recent positive post about ActiPatch on facebook.
Terrie Leisher
2 hrs
Never used it for this pain before....but my wrist has been bothering me for the last few days. I was staying at my daughter's house and didn't have my ActiPatch with me. So when I returned home today, I immediately taped-on the ActiPatch. It was a bad fit in that area....but I managed to keep it in place for a few hours. I just took it off to shower and my wrist pain is already better. I'll do it again tomorrow when I get up!
ActiPatch is a great product. It easily reaches to 23 cents or 25 cents by end of 2019 year.
Great review about Actipatch on the facebook.
Rosemarie Mcardle
Yesterday at 6:28 AM
Just a few comments while they are still in my head. On Tuesday morning i discovered that my beloved Actipatch died during the night :) So i head for Dundalk, Co Louth Eire to purchase one. Boots where i always got them........Well i could have more easily asked for a return ticket to Mars............".Try a hot water bottle" she says. Grrrr. Another Pharmacy....."Try Amazon". I need it tonight sunshine. Next morning Newry. Co Down NI. Boots " You have to order it" Grrr. Superdrug, whheeyhheee £12/99. I always gave £25 in Boots. So don't know if it's all Superdrug or just my local, but brilliant value. Just another point in case there are still doubters out there. This morning i'm in bed on my Laptop. I have a stabbing pain in it's usual place, just over my left hip. Like a hot needle jabbing at regular intervals. Took my Actipatch, Put it under my back, one more stab of pain and blessed relief. So if that's not proof, i don't know what is. Keep up the good work Actipatch. Iv'e converted two people this week so far.
Suppose If FDA doesn't approve, what is the next? Do they can re apply?
Did BIEL receive any email from FDA since it is passed the 90 days?
May be, FDA is planing to clear all products (Actipatch, allay and recovery RX) of BIEL at the same time. That's way, they are taking more time.
We thought, we are going to have FDA approval today. Is any news on that?
Why is going down? Any bad news?
What is convertible debt means?
Someone just bought about 7 million shares at 0.0022
Some of Biel share holders are loosing their patience that why they are selling in low.
Seven-up, Is HealFast Therapy owned by Biel?
Why is stock being sold in low price? Every one knows, FDA approval will be announced very soon. It is still struggling to settle down between 0.0022 and 0.0023.
If someone buys this company, what will happen to our shares?
Chronic pain cost per every year is $640 billion just in USA. BIEL just needs only $5 billion every year to maintain the stock price 25 cents. Once BIEL receives all FDA approvals, it is easy to reach as a $5 billion company.
Are they going to approve all these ActiPatch Therapy; Allay; RecoverRx three at the same time?
Proprietary Name: ActiPatch Therapy; Allay; RecoverRx
Classification Name: DIATHERMY, SHORTWAVE, FOR USE OTHER THAN APPLYING THERAPEUTIC DEEP HEAT
Product Code: ILX
Device Class: 2
Regulation Number: 890.5290
Medical Specialty: Physical Medicine
Registered Establishment Name: BIOELECTRONICS CORPORATION
Registered Establishment Number: 3004837702
Premarket Submission Number: K022404
Owner/Operator: BioElectronics Corporation
Owner/Operator Number: 10028114
Establishment Operations: Manufacturer
how much chance of getting FDA approval even we wait for 180 days?
As per Paul, The FDA’s goal is to clear 510(k)’s within 90 days, which happens in less than 20% of the time. The average is slightly less than 180 days.
See the response from Paul.
10:20 AM (2 hours ago)
Hi Paul, Did you recently get any additional questions again from FDA? Thanks, Nag
Outlook-Mail-Sync
1:05 PM (5 minutes ago)
to me
No.
Paul K.
Two weeks back, I visited google,FB,MSFT,C,HBAN,AMAZON ETC conversation boards on Yahoo and posted about BIEL. You can also do so that the interested investors can invest on BIEL.